Company Analysis
Sign in

Akari Therapeutics plc (AKTX)

Nasdaq: AKTX · Pharmaceutical Preparations · Tampa, FL · filing with the SEC since 2012
Full chart Alerts Compare
Grade3.5
◀ Past 3.4● Present 3.0▶ Future 3.8
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$17.3M+12.6%
Earnings per share$0.00
Operating cash flow-$10.6M+15.8%
Cash$0.00
Debtn/a
Shareholders’ equity$28.3M+27.4%
Shares, diluted67.33B+181.8%
Return on equity-61.1%
The recordfrom its filings
Filings in 202659
Newest filingNov 12 · 8-K
Annual reportMar 30, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted8
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$29.4MCash from operations -$12.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Nov 12, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton AKTX · research, not advice